
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol. , 30 January 2018
Sec. Inflammation Pharmacology
Volume 9 - 2018 | https://doi.org/10.3389/fphar.2018.00022
A retraction of this article was approved in:
Retraction: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5
RETRACTED: Corrigendum: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5
Citation: Xin Z, Jin C, Chao L, Zheng Z, Liehu C, Panpan P, Weizong W, Xiao Z, Qingjie Z, Honggang H, Longjuan Q, Xiao C and Jiacan S (2018) A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5. Front. Pharmacol. 9:22. doi: 10.3389/fphar.2018.00022
Received: 25 July 2017; Accepted: 08 January 2018;
Published: 30 January 2018; Retracted: 19 February 2025.
Edited by:
Patrizia Ballerini, Università degli Studi “G. d’Annunzio” Chieti – Pescara, ItalyReviewed by:
Satish Ramalingam, SRM University, IndiaDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.